Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals
Novavax's (NVAX) stock was trading down more than 6% Tuesday afternoon after the company lowered its guidance for sales for ...
KSL2d
FDA lifts clinical hold on Novavax's combo COVID-flu shot
The Food and Drug Administration has lifted its clinical hold on a late-stage trial of Novavax's COVID-influenza and its ...
Novavax: Navigating Fiscal Challenges and Strategic Shifts Amid COVID Vaccine Market Uncertainty
In a report released today, Brendan Smith from TD Cowen maintained a Hold rating on Novavax (NVAX – Research Report), with a price target ...
Novavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...
Novavax Lowers 2024 Forecast Despite Q3 Revenue Beat, Stock Falls
Novavax reports Q3 2024 sales of $84.5 million, beating estimates, with a net loss of $121 million. EPS improves, FDA ...
Novavax: Balancing Potential and Risk Amid Strategic Shifts and Uncertain Market Outlook
Analyst Alec Stranahan of Bank of America Securities reiterated a Hold rating on Novavax (NVAX – Research Report), reducing the price ...
Novavax: Q3 Earnings Snapshot
GAITHERSBURG, Md. (AP) — GAITHERSBURG, Md. (AP) — Novavax Inc. (NVAX) on Tuesday reported a loss of $121.3 million in its third quarter. On a per-share basis, the Gaithersburg, Maryland-based company ...
Spotlight on Novavax: Analyzing the Surge in Options Activity
We gleaned this information from our observations today when Benzinga's options scanner highlighted 9 extraordinary options activities for Novavax. This level of activity is out of the ordinary.
Novavax price target lowered to $12 from $14 at BofA
BofA lowered the firm’s price target on Novavax (NVAX) to $12 from $14 and keeps a Neutral rating on the shares. The company announced ...